Didemnin B vs Apratoxin A
Head-to-head comparison of Didemnin B (Didemnin B) and Apratoxin A (Apratoxin A) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Didemnin B | Apratoxin A |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | Didemnin B | Apratoxin A |
| Molecular Weight | 1112.4 Da | N/A |
| Half-Life | N/A | N/A |
| Amino Acids | N/A | N/A |
| Typical Dose | 0.05-2 mg/m2 IV in early trials | N/A in humans; nanomolar in vitro |
| Route | Intravenous | Intraperitoneal / Intravenous (preclinical) |
| Purity | ≥98% | ≥98% |
| Studies Count | 120 | 140 |
| Research Status | Clinical | Pre-clinical |
Didemnin B Benefits
- ✓antineoplastic
- ✓antiviral
- ✓pro-apoptotic
- ✓immunomodulatory
Apratoxin A Benefits
- ✓antineoplastic
- ✓anti-angiogenic
- ✓Sec61 inhibition
- ✓anti-proliferative
Didemnin B Dosing
historic IV phase I/II oncology regimens|dose escalation in early trials|no approved dosing regimen
Apratoxin A Dosing
preclinical in vitro nanomolar use|animal studies only|no human dosing established
Didemnin B Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠myelosuppression
Apratoxin A Side Effects
- ⚠hepatotoxicity
- ⚠general cytotoxicity
- ⚠GI toxicity
Research Overview
Didemnin B
Didemnin B showed strong cytotoxic and antiviral activity in early literature and became an important scaffold for later marine drug development. Its clinical progress was limited by toxicity, but it remains highly cited as a foundational marine depsipeptide.
Apratoxin A
Apratoxin A is a well-studied lead compound for targeting secretory and membrane protein biogenesis in cancer cells. Medicinal chemistry programs around apratoxins focus on improving selectivity and reducing hepatotoxicity while preserving potency.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.